Article Figures & Data
Figures
- Figure 1
Clinical trial schema. Bladder cancer patients are treated with 2 doses of anti-CTLA-4 antibody at 3 mg/kg at study weeks 0 and 3 prior to undergoing surgery at study week 7 and post-operative follow-up visits at study weeks 11-15 and 23-24. Blood is collected as: pre-therapy samples prior to administration of the first dose of antibody at study week 0; after dose #1 at study week 3 prior to administration of dose #2; after dose #2 at study week 7 prior to surgery; and at each post-op visit.
- Figure 2
Increased plasma concentrations of IFN-γ detected after administration of anti-CTLA-4 antibody. All 4 patients analyzed thus far had elevated levels of IFN-γ detected in plasma samples collected after the first and second doses of anti-CTLA-4 antibody as compared to pre-therapy levels. IFN-γ levels decreased in the post-operative setting consistent with no further administration of antibody. Healthy donors (HD, n = 10) were found to have low concentrations of plasma IFN-γ similar to the pre-therapy values seen in the bladder cancer patients.
- Figure 3
Decreased plasma concentration of IL-10 in one patient after treatment with anti-CTLA-4 antibody. Patients treated with anti-CTLA-4 antibody were found to have low levels of plasma IL-10 concentrations, similar to values seen for healthy donors (HD, n = 10), except for one patient (patient CW). Patient CW had a high pre-therapy concentration of plasma IL-10 which decreased after treatment with anti-CTLA-4 antibody and then increased again in the post-operative setting which lacks anti-CTLA-4 antibody administration. Patient CW's immune-related adverse event (irAE) coincided with the decrease in IL-10 levels (black arrow).
- Figure 4
Visual examination of patient CW. Humphrey's visual field 30-2 (study week 13) of the right eye (OD) with an inferior arcuate scotoma and of the left eye (OS), with both superior and inferior arcuate scotomas.
- Table 1
Documented events for patient CW while enrolled on a clinical trial protocol consisting of treatment with anti-CTLA-4 antibody.
Volume 8, Issue 1
